Journals / Annals of Medical Research / 2020 / Cilt: 27 - Sayı: 5

Our surgical experience in cholangiocellular carcinoma

Pages
1415–1421
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean survival time was 22.82(±13.72) months.Conclusion: The type of surgical approach to be performed in cholangiocellular carcinoma is related to the localization of the tumor.With the right patient selection, curative surgical treatment can be performed at low morbidity and mortality rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Cholangiocellular carcinomas are rare bile duct tumors.
📊
Key Findings & Data:In this study, we aimed to present our clinical experiencein patients with cholangiocellular carcinoma.Material and Methods: Patients who underwent curative surgery with the diagnosis of cholangiocellular carcinoma between 2010and 2019 were retrospectively reviewed.
💡
Conclusion & Impact:The mean survival time was 22.82(±13.72) months.Conclusion: The type of surgical approach to be performed in cholangiocellular carcinoma is related to the localization of the tumor.With the right patient selection, curative surgical treatment can be performed at low morbidity and mortality rates.
🔬Design:Review & Systematic Survey
📍Scope:2019 Verileri
⚙️Variables:Domain Parameters

Abstract

Aim: Cholangiocellular carcinomas are rare bile duct tumors. They are categorized as intrahepatic(iCCA), perihilar(pCCA) ordistal(dCCA) cholangiocarcinomas according to their anatomical location. In this study, we aimed to present our clinical experiencein patients with cholangiocellular carcinoma.Material and Methods: Patients who underwent curative surgery with the diagnosis of cholangiocellular carcinoma between 2010and 2019 were retrospectively reviewed. Demographic and clinical characteristics, surgical procedures, tumor characteristics, shortand long-term results and survival of the patients were analyzed.Results: Twentynine patients were included in the study. The mean age of the patients was 63.3(±10.8) years, and 52% of the patientswere older than 65 years. Male sex was 79.3%. Percutaneous biliary drainage was performed in 52% of the patients before theoperation. Tumor localizations were distal (dCCA) in 12 (41.4%) patients, perihilar (pCCA) in 11 (38%) patients, and intrahepatic (iCCA)in 6 (20.6%) patients. Only biliary resection was performed in 69%, hepatic + biliary resection in 27.6%, and only hepatic resectionin 3.4% of the patients. The mean tumor size was 3.08 cm (±1.91), tumor stage was commonly stage II (58.6%) and postoperativecomplication was seen in 13.8% of the patients. Ninety-day unplanned readmission was observed in 31.3%, postoperative mortalityin 6.9%, and recurrence during postoperative follow-up in 24.2% of the patients. The mean survival time was 22.82(±13.72) months.Conclusion: The type of surgical approach to be performed in cholangiocellular carcinoma is related to the localization of the tumor.With the right patient selection, curative surgical treatment can be performed at low morbidity and mortality rates.

🔖

Cite This Article

TOPAL, U., SARITAŞ, A. G., ÜLKÜ, A., DALCI, K., AYDIN, E., AKÇAM, A. T. (2022). Our surgical experience in cholangiocellular carcinoma. Annals of Medical Research, Cilt: 27 - Sayı: 5, 1415–1421. https://ajindex.com/articles/446442

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Olnes MJ, Erlich R. A reviewandupdate on cholangiocarcinoma.Oncology 2004
  2. 79 2. Razumilava N, Gores GJ. Cholangiocarcinoma. The Lancet 2014
  3. 3832168-79. 3. Lewis HL, Rahnemai-Azar AA, Dillhoff M, et al. Current management of perihilar cholangiocarcinoma and future perspectives. Chirurgia 2017
  4. Khan SA, Thomas HC, Davidson B R, et al. Cholangiocarcinoma. The Lancet 2005
  5. Bergquist A, vonSeth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol 2015
  6. Hidalgo E, Asthana S, Nishio H, et al. Surgeryforhilarcholangiocarcinoma: the Leeds experience. Eur J Surg Oncol 2008
  7. Silva MA, Tekin K, Aytekin F, et al Surgery for hilar cholangiocarcinoma
  8. a 10 year experience of a tertiary referral centre in the UK. Eur J Surg Oncol 2005
  9. Neumann UP, Schmeding M. Role of surgeryin cholangiocarcinoma: from resection to transplantation. Best Pract Res Clin Gastroenterol 2015
  10. Lee SG, Song GW, Hwang S, et al. Surgical treatment of hilar cholangiocarcinoma in the new era: the Asan experience. J Hepatobiliary Pancreat Sci 2010
  11. Cillo U, Fondevila C, Donadon M, et al. Surgery for cholangio carcinoma. Liver Int 2019
  12. DeOliveira ML, Cunningham SC, Cameron JL,et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007
  13. Ahrendt SA, Pitt HA. Biliary tract. In: Townsend C, editor.Sabiston Textbook of Surgery. Philadelphia: W.B. Saunders Company 2001:1076-11. 13. Everhart JE, Ruhl CE. Burden of digestive diseases in the UnitedStates Part III: Liver, biliary tract, and pancreas. Gastroenterology 2009
  14. Anderson CD, Pinson CW, Berlin J, et al. Diagnosis and treatment of cholangiocarcinoma. The oncologist 2004
  15. 1RARECARE project, Surveillance of Rare Cancers in Europe. Incidence (1995–2002)in Europe by sex, age, and EU region with expected new case in EU (27) in 2008 Available at: http://dcnapp4. dcn.ed.ac.uk/rcnet/searchpage.aspx. 16. Squadroni M, Tondulli L, Gatta G, et al. Cholangiocarcinoma. Crit Rev Oncol Hematol 2017
  16. Kimmings AN, van Deventer SJ, Obertop H, et al. Inflammatory and immunologic effects of obstructive jaundice: pathogenesis and treatment. J Am Coll Surg 1995
  17. Hu QL, Liu JB, Ellis RJ, et al Association of preoperative biliary drainage technique with postoperative outcomes among patients with resectable hepatobili